Received: 22 August 2017
Accepted: 10 July 2019
First Online: 29 July 2020
Change Date: 5 January 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-020-03067-w
: E.L.V.N. is a co-founder, member of the Board of Directors, equity holder and paid consultant for Eclipse BioInnovations Inc. G.W.Y. is co-founder, member of the Board of Directors, on the SAB, equity holder and paid consultant for Locana and Eclipse BioInnovations Inc. G.W.Y. is a distinguished visiting professor at the National University of Singapore. E.L.V.N.’s and G.W.Y.’s interest(s) have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. C.B.B. is a scientific advisory board member and equity option holder of Arrakis Therapeutics Inc. The authors declare no other competing financial interests.